Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to -$642810.0.

  • Mangoceuticals' Change in Accured Expenses fell 567495.28% to -$642810.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$82334.0, marking a year-over-year decrease of 11331.27%. This contributed to the annual value of $696736.0 for FY2024, which is 55060.79% up from last year.
  • As of Q3 2025, Mangoceuticals' Change in Accured Expenses stood at -$642810.0, which was down 567495.28% from $89816.0 recorded in Q2 2025.
  • In the past 5 years, Mangoceuticals' Change in Accured Expenses registered a high of $875180.0 during Q1 2024, and its lowest value of -$642810.0 during Q3 2025.
  • In the last 3 years, Mangoceuticals' Change in Accured Expenses had a median value of $51706.0 in 2023 and averaged $54997.8.
  • In the last 5 years, Mangoceuticals' Change in Accured Expenses skyrocketed by 15138.67% in 2024 and then tumbled by 567495.28% in 2025.
  • Mangoceuticals' Change in Accured Expenses (Quarter) stood at $51706.0 in 2023, then surged by 151.39% to $129982.0 in 2024, then plummeted by 594.54% to -$642810.0 in 2025.
  • Its Change in Accured Expenses was -$642810.0 in Q3 2025, compared to $89816.0 in Q2 2025 and $340678.0 in Q1 2025.